NO20073921L - Triazoloftalaziner - Google Patents
TriazoloftalazinerInfo
- Publication number
- NO20073921L NO20073921L NO20073921A NO20073921A NO20073921L NO 20073921 L NO20073921 L NO 20073921L NO 20073921 A NO20073921 A NO 20073921A NO 20073921 A NO20073921 A NO 20073921A NO 20073921 L NO20073921 L NO 20073921L
- Authority
- NO
- Norway
- Prior art keywords
- triazoloftalaziner
- compounds
- formula
- description
- meanings given
- Prior art date
Links
- 229940121828 Phosphodiesterase 2 inhibitor Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05100045 | 2005-01-05 | ||
| EP05100044 | 2005-01-05 | ||
| PCT/EP2006/050041 WO2006072615A2 (en) | 2005-01-05 | 2006-01-04 | Triazolophthalazines as pde2-inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073921L true NO20073921L (no) | 2007-07-26 |
Family
ID=36604687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073921A NO20073921L (no) | 2005-01-05 | 2007-07-26 | Triazoloftalaziner |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8106047B2 (https=) |
| EP (1) | EP1836207B1 (https=) |
| JP (1) | JP5240899B2 (https=) |
| KR (1) | KR20070095986A (https=) |
| CN (1) | CN101103033B (https=) |
| AU (1) | AU2006204454B2 (https=) |
| BR (1) | BRPI0606379A2 (https=) |
| CA (1) | CA2592007C (https=) |
| EA (1) | EA012505B1 (https=) |
| ES (1) | ES2397080T3 (https=) |
| IL (1) | IL183919A (https=) |
| MX (1) | MX2007008137A (https=) |
| NO (1) | NO20073921L (https=) |
| NZ (1) | NZ555661A (https=) |
| WO (1) | WO2006072615A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101368093B1 (ko) * | 2004-09-02 | 2014-03-14 | 다케다 게엠베하 | 트리아졸로프탈라진 |
| CN101103033B (zh) | 2005-01-05 | 2010-08-04 | 尼科梅德有限责任公司 | 作为pde2抑制剂的三唑并酞嗪 |
| CA2591991C (en) * | 2005-01-05 | 2013-11-19 | Altana Pharma Ag | Triazolophthalazines |
| PH12012501361A1 (en) | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| CA2836851C (en) * | 2011-06-07 | 2016-06-21 | Christopher J. Helal | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
| NZ631258A (en) | 2012-04-25 | 2016-11-25 | Takeda Pharmaceuticals Co | Nitrogenated heterocyclic compound |
| WO2013166276A1 (en) * | 2012-05-02 | 2013-11-07 | Southern Research Institute | Triazolopyridazine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof |
| WO2014010732A1 (ja) * | 2012-07-13 | 2014-01-16 | 武田薬品工業株式会社 | 複素環化合物 |
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| EP2975031A4 (en) | 2013-03-14 | 2017-04-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3018123B1 (en) | 2013-07-03 | 2023-05-10 | Takeda Pharmaceutical Company Limited | Amide compound |
| JP6427491B2 (ja) | 2013-07-03 | 2018-11-21 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6696904B2 (ja) | 2014-01-08 | 2020-05-20 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 製剤および医薬組成物 |
| CN103694244B (zh) * | 2014-01-09 | 2016-03-30 | 郑州大学 | 3,6位取代-1,2,4-三氮唑并[3,4-a]酞嗪类化合物及其制备和用途 |
| HUE057317T2 (hu) | 2014-04-23 | 2022-04-28 | Dart Neuroscience Llc | Helyettesített [1,2,4]triazolo[1,5-A]pirimidin-7-IL vegyületeket tartalmazó készítmények mint PDE2 inhibítorok |
| TWI568737B (zh) | 2014-11-05 | 2017-02-01 | 達特神經科學（開曼）有限責任公司 | 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物 |
| CA2969594A1 (en) | 2014-12-06 | 2016-06-09 | Intra-Cellular Therapies, Inc. | Pde2 inhibiting organic compounds |
| HK1244427A1 (zh) | 2014-12-06 | 2018-08-10 | Intra-Cellular Therapies, Inc. | 有机化合物 |
| WO2016145614A1 (en) * | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
| WO2016154081A1 (en) | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
| WO2016179059A1 (en) | 2015-05-05 | 2016-11-10 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as pde2 inhibitors |
| WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
| WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| WO2016192083A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| US10647727B2 (en) | 2015-06-25 | 2020-05-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors |
| WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
| EP3156405A1 (en) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| AU2018371216B2 (en) | 2017-11-23 | 2024-09-19 | Oslo University Hospital Hf | Treatment of tachycardia |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH21834A (en) * | 1982-01-18 | 1988-03-17 | Lepetit Spa | New 6-substituted-s-triazolo(3,4-a)phthalazine derivatives |
| IT1194310B (it) * | 1983-07-12 | 1988-09-14 | Lepetit Spa | Derivati triazolo (3,4-a) ftalazinici 3,6-disostituiti |
| US5869486A (en) | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
| KR20000029548A (ko) | 1996-07-25 | 2000-05-25 | 더블유. 지. 콜 | 가바수용체에대한리간드로서의치환된트리아졸로-피리다진유도체 |
| CA2288789C (en) | 1997-05-08 | 2009-07-21 | Merck Sharp & Dohme Limited | Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as gaba alpha 5 ligands |
| US6235741B1 (en) * | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
| GB9715977D0 (en) | 1997-07-29 | 1997-10-01 | Merck Sharp & Dohme | Therapeutic agents |
| IT1303272B1 (it) * | 1998-10-29 | 2000-11-06 | Zambon Spa | Derivati triciclici inibitori della fosfodiesterasi 4 |
| WO2001047929A1 (de) * | 1999-12-24 | 2001-07-05 | Bayer Aktiengesellschaft | Triazolotriazinone und ihre verwendung |
| GB0028583D0 (en) * | 2000-11-23 | 2001-01-10 | Merck Sharp & Dohme | Therapeutic compounds |
| US6958334B2 (en) | 2001-04-10 | 2005-10-25 | Merck & Co., Inc. | Inhibitors of Akt activity |
| CA2497539A1 (en) | 2002-09-04 | 2004-03-18 | Schering Corporation | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US20070179161A1 (en) | 2003-03-31 | 2007-08-02 | Vernalis (Cambridge) Limited. | Pyrazolopyrimidine compounds and their use in medicine |
| KR101368093B1 (ko) * | 2004-09-02 | 2014-03-14 | 다케다 게엠베하 | 트리아졸로프탈라진 |
| CA2591991C (en) * | 2005-01-05 | 2013-11-19 | Altana Pharma Ag | Triazolophthalazines |
| CN101103033B (zh) | 2005-01-05 | 2010-08-04 | 尼科梅德有限责任公司 | 作为pde2抑制剂的三唑并酞嗪 |
-
2006
- 2006-01-04 CN CN2006800017646A patent/CN101103033B/zh not_active Expired - Fee Related
- 2006-01-04 EP EP06700240A patent/EP1836207B1/en not_active Expired - Lifetime
- 2006-01-04 MX MX2007008137A patent/MX2007008137A/es active IP Right Grant
- 2006-01-04 WO PCT/EP2006/050041 patent/WO2006072615A2/en not_active Ceased
- 2006-01-04 CA CA2592007A patent/CA2592007C/en not_active Expired - Fee Related
- 2006-01-04 EA EA200701396A patent/EA012505B1/ru not_active IP Right Cessation
- 2006-01-04 US US11/794,145 patent/US8106047B2/en not_active Expired - Fee Related
- 2006-01-04 BR BRPI0606379-9A patent/BRPI0606379A2/pt not_active IP Right Cessation
- 2006-01-04 JP JP2007548843A patent/JP5240899B2/ja not_active Expired - Fee Related
- 2006-01-04 ES ES06700240T patent/ES2397080T3/es not_active Expired - Lifetime
- 2006-01-04 KR KR1020077017407A patent/KR20070095986A/ko not_active Ceased
- 2006-01-04 AU AU2006204454A patent/AU2006204454B2/en not_active Ceased
- 2006-01-04 NZ NZ555661A patent/NZ555661A/en not_active IP Right Cessation
-
2007
- 2007-06-14 IL IL183919A patent/IL183919A/en not_active IP Right Cessation
- 2007-07-26 NO NO20073921A patent/NO20073921L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006072615A2 (en) | 2006-07-13 |
| IL183919A (en) | 2011-06-30 |
| IL183919A0 (en) | 2007-10-31 |
| ES2397080T3 (es) | 2013-03-04 |
| WO2006072615A3 (en) | 2007-01-04 |
| KR20070095986A (ko) | 2007-10-01 |
| EA200701396A1 (ru) | 2007-12-28 |
| AU2006204454A1 (en) | 2006-07-13 |
| JP2008526717A (ja) | 2008-07-24 |
| JP5240899B2 (ja) | 2013-07-17 |
| BRPI0606379A2 (pt) | 2009-06-23 |
| CA2592007A1 (en) | 2006-07-13 |
| CA2592007C (en) | 2013-12-10 |
| EP1836207B1 (en) | 2012-10-10 |
| US8106047B2 (en) | 2012-01-31 |
| EP1836207A2 (en) | 2007-09-26 |
| AU2006204454B2 (en) | 2011-11-10 |
| HK1116776A1 (en) | 2009-01-02 |
| CN101103033B (zh) | 2010-08-04 |
| US20080312225A1 (en) | 2008-12-18 |
| EA012505B1 (ru) | 2009-10-30 |
| MX2007008137A (es) | 2007-07-19 |
| CN101103033A (zh) | 2008-01-09 |
| NZ555661A (en) | 2010-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073921L (no) | Triazoloftalaziner | |
| NO20071127L (no) | Triazoloftalaziner | |
| BRPI0608886B8 (pt) | derivados de n-sulfonilpirróis e seus usos | |
| BR0313330A (pt) | Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4 | |
| NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
| NO20081797L (no) | Nye solfonylpyrroler som inhibitorer av HDAC | |
| CY1109911T1 (el) | Πυρρολοβενζοδιαζεπινες | |
| TW200640924A (en) | VEGF-R2 inhibitors and methods | |
| NO20070731L (no) | Heterocykliske forbindelser. | |
| NO20083694L (no) | Bruk av rylener som markorer for vaesker | |
| EA200801428A1 (ru) | Производные пиридиазинона для лечения опухолей | |
| NO20075987L (no) | Bisykliske derviater som p38-kinaseinhibitorer | |
| NO20080061L (no) | Imidazolyl-pyrimidinforbindelser for anvendelse til behandling av proliferative lidelser | |
| NO20076345L (no) | Bisykliske derivater som P38-kinaseinhibitorer | |
| NO20082105L (no) | Pyrazoloisokinolinderivater | |
| EA200601568A1 (ru) | Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4 | |
| TW200745027A (en) | Novel sulphonylpyrroles | |
| NO20080265L (no) | 2-(1H-indolylsulfanyl)-arylaminderivater | |
| WO2006072612A3 (en) | Triazolophthalazines as pde2- inhibitors | |
| UA85505C2 (en) | Kinase inhibitors | |
| EA201270630A1 (ru) | Гетероциклические сетр ингибиторы | |
| EA200901504A1 (ru) | Производные пиразолона, как ингибиторы pde4 | |
| EA200800357A1 (ru) | Новые фармацевтические соединения | |
| NO20080144L (no) | Spiro-benzimidazoler som inhibitorer av magesyre og sekresjon | |
| NO20061789L (no) | Aminopyridinderivater som induserbare NO-syntaseinhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104 |
|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: TAKEDA GMBH, DE |
|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: TAKEDA GMBH, DE |
|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |